eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
helen was proud and extremely independent, but had a soft, elegant side to her.
.. a little under 60% of these encounters resulted in hospitalization and of these, about 13% required intensive care.
.
november 17, 2014
.